Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Unity Biotechnology. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Unity Biotechnology's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Unity Biotechnology is high growth as no earnings estimate data is available.
Unity Biotechnology's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Unity Biotechnology's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Unity Biotechnology's finances.
The net worth of a company is the difference between its assets and liabilities.
Unity Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Unity Biotechnology's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Unity Biotechnology's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Unity Biotechnology has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Keith R. Leonard, Jr., M.S., M.B.A., serves as a Venture Partner at Arch Venture Partners, L.P. Mr. Leonard serves as the Executive Chairman and Chief Executive Officer of Unity Biotechnology, Inc. Mr. Leonard has more than 20 years of experience in the pharmaceutical industry. He serves as the President and Chief Executive Officer at AESTHERx Inc. He serves at UCLA Venture Capital Fund. He served as the Chief Executive Officer and President of Kythera Biopharmaceuticals, Inc from August 2005 to October 1, 2015. He co-founded Kythera Biopharmaceuticals, Inc in 2005. He served as a Senior Vice president and General Manager at Amgen Europe and was responsible for all commercial operations in 28 countries. From May 1995 to August 1995, Mr. Leonard was responsible to help set up the company's manufacturing operations. His career at Amgen Europe included establishing Amgen's presence in rheumatology with the creation of the Rheumatology Business Unit, Head of Information Management and leadership roles in Sales and Marketing, Engineering, Operations and Finance. Mr. Leonard is a 13-year Veteran of Amgen Inc. He expanded its operations into 11 additional countries and oversaw numerous successful product launches. As a Vice President for its rheumatology business unit, he prepared the launch of arthritis drug Kineret. He has been the Chairman at Sienna Biopharmaceuticals, Inc. since January 2016. He has been a Director at Intuitive Surgical, Inc. since January 28, 2016 and Laboratoris Sanifit, S.L. since May 2016. Mr. Leonard served as a Director of Affymax, Inc. from December 2007 to June 4, 2013. He served as an Independent Director of Anacor Pharmaceuticals, Inc. from May 30, 2014 to June 24, 2016. Mr. Leonard served as a Director of Kythera Biopharmaceuticals, Inc from August 2005 to October 1, 2015. He served as an Independent Director of ARYx Therapeutics, Inc. from September 2005 to February 1, 2011. He was formerly an active duty officer in the US Navy. Mr. Leonard received a Master of Business Administration from The Anderson School of Management, University of California, Los Angeles between 1993 to 1995, a Master of Science in Mechanical Engineering from University of California, Berkeley between 1988 to 1990, a Bachelor of Arts in History from University of Maryland, College Park between 1985 to 1987 and a Bachelor of Science in Engineering from University of California, Los Angeles between 1979 to 1984.
Insufficient data for Keith to compare compensation growth.
Keith's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Unity Biotechnology management team is about average.
Executive Chairman & CEO
Chief Financial Officer
Jan van Deursen
Senior Vice President of Operations
Chief Scientific Officer
General Counsel & Corporate Secretary
Senior Vice President of Corporate Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Unity Biotechnology board of directors is about average.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.